-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Lowered to $42 at Barclays
-
-
-
-
-
-
-
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $33 at TD Cowen
-
-
-
-
-
-
-
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
-
-
-
-
-
-
-
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) anticipates FY20 net product revenues for DMD franchise to be between $320 and $340 million
-
-
-
-
-
-
-
JPMorgan Downgrades PTC Therapeutics (PTCT) to Underweight Citing Mixed Updates and Valuation
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

